Oncology Medical News about Thiazolidinediones

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells
Clinical Endocrinology, 06/01/09

Antonelli A et al. – Data demonstrate that thiazolidinediones exert an antiproliferative effect in primary cultured human anaplastic carcinoma cells in vitro, such as antiblastics.

Methods

An evaluation of the antiproliferative effects of thiazolidinediones and antiblastics in primary cultured human anaplastic thyroid cancer cells
Proliferation was evaluated after incubation with increasing concns of rosiglitazone or pioglitazone or antiblastics (bleomycin, cisplatin, gemcitabine)
Methods used: proliferation assay (WST-1-tetrazolium reaction) and cell counting

Results

A reduction of proliferation was seen by thiazolidinediones at 1 hour:
- 11% and 25%, with rosiglitazone, with 10 or 20 µM, respectively
- 7% and 17%, with pioglitazone, with 10 or 20 µM, respectively
Reduction of proliferation at 2 hours:
- 14% and 24%, with rosiglitazone with 10 or 20 µM, respectively
- 9% and 21%, with pioglitazone with 10 or 20 µM, respectively
No significant effect was observed in normal thyroid follicular cells
Bleomycin, cisplatin and gemcitabine inhibited (>50%) anaplastic cells proliferation, confirmed by cell counting
Inhibition of proliferation was similar in tumours with or w/o V600EBRAF mutation, both for thiazolidinediones and antiblastics